These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 13963684)

  • 1. Review of the Louisiana State Board of Health experience with the use of Salk vaccine and comments on the Sabin oral polio vaccine.
    HEDMEG A
    J La State Med Soc; 1963 Feb; 115():41-7. PubMed ID: 13963684
    [No Abstract]   [Full Text] [Related]  

  • 2. Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains.
    CHUMAKOV MP
    Bull World Health Organ; 1961; 25(1):79-91. PubMed ID: 13879389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
    Shimizu H
    Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RESPONSE TO ONE DOSE OF TRIVALENT ORAL POLIOVACCINE IN CHILDREN PREVIOUSLY IMMUNISED WITH SALK VACCINE: A COMPARISON OF LIQUID VACCINE AND A CAPSULE PRESENTATION.
    BEALE AJ; DAVIES JR; THROWER AL
    Lancet; 1965 Apr; 1(7391):879-81. PubMed ID: 14272682
    [No Abstract]   [Full Text] [Related]  

  • 5. [Killed (Salk type) or living (Sabin type) poliomyelitis vaccine?].
    VERLINDE JD
    Ned Tijdschr Geneeskd; 1962 Dec; 106():2599-604. PubMed ID: 13996794
    [No Abstract]   [Full Text] [Related]  

  • 6. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
    Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicine and the media: polio still paralyses (Albert Sabin, Jonas Salk).
    Dixon B
    Br J Hosp Med; 1977 Dec; 18(6):595. PubMed ID: 342023
    [No Abstract]   [Full Text] [Related]  

  • 8. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
    Minor PD
    Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Universal use of inactivated poliovirus vaccine--the needs and challenges].
    Shimizu H; Takeda N
    Nihon Rinsho; 2008 Oct; 66(10):1950-5. PubMed ID: 18939495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
    Verdijk P; Rots NY; Bakker WA
    Expert Rev Vaccines; 2011 May; 10(5):635-44. PubMed ID: 21604984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
    J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects in the field of the antipolio vaccination (author's transl)].
    Focà A
    Ann Sclavo; 1980; 22(1):22-6. PubMed ID: 7018412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THE FUTURE OF INACTIVATED POLIOMYELITIS VACCINES.
    DANE DS
    Proc R Soc Med; 1964 Jun; 57(6):462-4. PubMed ID: 14190861
    [No Abstract]   [Full Text] [Related]  

  • 15. Sabin and Salk poliovirus vaccine: vice versa.
    Cohen HH
    Acta Leiden; 1987; 56():65-83. PubMed ID: 3329800
    [No Abstract]   [Full Text] [Related]  

  • 16. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the development of natural immunity to poliomyelitis in Louisiana. VI. The incidence of poliovirus infections during 1958 as an indication of the effect of Salk-type vaccine on virus dissemination.
    POTASH L; GELFAND HM; FOX JP
    Am J Hyg; 1960 May; 71():418-26. PubMed ID: 14434441
    [No Abstract]   [Full Text] [Related]  

  • 18. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibody response in subjects vaccinated with a recall dose of the Sabin or Salk type vaccine].
    Squeri L; Calisto ML; Sindoni L; Mattace-Raso G
    Ann Sclavo; 1973; 15(6):569-80. PubMed ID: 4369487
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on the development of natural immunity to poliomyelitis in Louisiana. III. The serologic response to commercially produced "Salk vaccine" of children totally or partially susceptible to poliovirus infection.
    GELFAND HM; LeBLANC DR; FOX JP; POTASH L
    Am J Hyg; 1959 Nov; 70():303-11. PubMed ID: 13827181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.